Table 4.
Univariable and multivariable analysis for overall survival (OS)
| Variables | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Treatment regimen | ||||
| mFOLFIRINOX vs Gemox | 0.595 (0.312–1.135) | 0.099 | 0.547 (0.264–1.131) | 0.103 |
| Age | ||||
| >58 vs ≤58 | 1.089 (0.567–2.092) | 0.798 | ||
| Sex | ||||
| male vs female | 0.896 (0.650–1.235) | 0.504 | ||
| ECOG | ||||
| 1 vs 0 | 1.709 (0.883–3.310) | 0.112 | 2.148 (1.028–4.488) | 0.042 |
| Primary tumor sites | ||||
| Intrahepatic | Ref | |||
| Hilar | 1.609 (0.827–3.129) | 0.161 | 2.123 (1.023–4.402) | 0.043 |
| Distal | 0.893 (0.207–3.846) | 0.879 | 0.890 (0.199–3.983) | 0.878 |
| Disease status | ||||
| Metastasis vs Locally advanced | 0.939 (0.660–1.335) | 0.724 | ||
| Liver metastasis | 1.393 (0.716–2.710) | 0.329 | ||
| CA19–9 | ||||
| >40 vs ≤40 | 3.198 (1.237–8.266) | 0.016 | 4.972 (1.768–13.980) | 0.002 |
Bold values are statistically significant (p ≤ 0.05)
Ref reference, HR hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group